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Introduction
Brain-derived neurotrophic factor (BDNF) is a member 
of the neurotrophin family and has important functions in 
brain development, synaptogenesis, and memory and learn-
ing [19, 32, 37, 44, 50]. Disrupted BDNF function has been 
associated with several nervous system disorders, such as 
Huntington’s disease [23, 69], depression [8, 11], and anxi-
ety [55], in both humans and rodent models. In addition, 
BDNF is involved in several physiological processes out-
side the brain, such as angiogenesis in the heart and skeletal 
muscles [16], myogenic differentiation [49], and skeletal 
muscle regeneration [13]. As evident from studies with mice 
heterozygous for the BDNF gene, 50 % reduction in BDNF 
protein levels is sufficient to cause notable phenotypic 
changes [1, 2, 15, 45]. Thus, precise regulation of BDNF 
levels is important in several developmental and pathologi-
cal processes, highlighting the importance of understanding 
the mechanisms that control BDNF expression.
The 3′ untranslated regions (3′UTRs) of mammalian 
genes contain highly conserved sequences [60] important 
in the regulation of translational efficiency, polyadenyla-
tion, and stability of the mRNA. These functions are medi-
ated by binding to RNA-interacting factors, such as micro-
RNAs (miRs) [6, 48]. miRs are short, non-coding RNA 
molecules predicted to interact with the transcripts of about 
60 % of all mammalian protein-coding genes [7]. miRs 
bind their target mRNAs through a fully complementary 
seed sequence of 7–8 nucleotides in their 5′ end and less 
complementary area in the 3′ end, inducing translational 
repression and/or mRNA degradation [7, 24].
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One way to modulate miR-mediated regulation of 
gene expression is through the generation of alternative 
mRNA transcripts that differ in the length of the 3′UTR 
[58]. Brain-derived neurotrophic factor transcripts con-
tain either short (BDNF-SH, 350 nt) or long 3′UTR 
(BDNF-L, 2891 nt [27]). In addition to length, second-
ary structure of the 3′UTR is also known to influence 
mRNA stability, at least in part by modifying accessi-
bility to miR target sites in the mRNA [29, 67, 68]. In 
general, miR sites near the ends of the 3′UTR are more 
effective than sites in the center of the 3′UTR, partly 
because regions in the middle of the 3′UTR are more 
likely to be incorporated into hairpin structures, hinder-
ing access to miRs [29]. BDNF-L contains a stem-loop 
structure necessary for the regulation of transcript stabil-
ity [26], raising the possibility that a secondary structure 
could determine access to factors like miRs that influ-
ence mRNA stability.
Despite the presence of more than ten in silico pre-
dicted highly conserved binding sites for different miRs 
in BDNF 3′UTR (www.targetscan.org, see below) and 
the physiological and pathological relevance of BDNF 
levels, to date only a few miRs have been studied in rela-
tion to BDNF. Although BDNF regulation by miR-206 
has been well established in several studies [42, 47, 54], 
it has remained controversial which of the three miR-
206 sites is functional [42, 47]. The potential effect of 
another miR-1/206 family member, miR-1, which dif-
fers from miR-206 by four nucleotides outside the seed 
region and has a distinct expression pattern from miR-
206, has not been investigated to date. Other studies 
suggesting miR-BDNF 3′UTR interaction lack evidence 
that the effect of the putative BDNF-regulating miR on 
BDNF 3′UTR is direct [25, 46]. Most importantly, the 
effects of endogenous miRs on putative miR binding 
sites within BDNF 3′UTR have remained unaddressed 
altogether. Since 3′UTR length and secondary structure 
are likely to play an important role in miR-mediated tar-
get suppression [29, 58], the fact that all previous stud-
ies have exclusively analyzed BDNF 3′UTR fragments 
[25, 42, 46, 47] further stresses a need for analysis of 
BDNF 3′UTR-miR interaction in the context of native, 
full-length 3′UTR.
The objective of the current study was to analyze the 
regulation of both BDNF-L and BDNF-SH full-length 
3′UTR isoforms by ten miRs selected based on evolution-
ary conservation of their seed sequences within BDNF and 
their expression within tissues or cell lines with known 
BDNF function [21, 40, 49, 51, 61, 63]. We assessed the 
effects of miR-1, miR-10b, miR-15a, miR-16, miR-30a, 
miR-30b, miR-155, miR-182, miR-191 and miR-195 on 
full-length BDNF-L and BDNF-SH isoforms and identified 
miR-1, miR-10b, miR-155, and miR-191 as novel direct 
regulators of BDNF 3′UTR. In addition, we provide data 
suggesting direct interaction between BDNF long 3′UTR 
and endogenous miR-1/206 family miRs in a model system 
of muscle differentiation, where the regulation of BDNF 
levels is known to be critical. Finally, our results indicate 
that the binding sites for miR-1 and miR-10 in BDNF 




Full-length and short BDNF 3′UTR sequences were 
obtained from BAC clone RP24-149F11 (RPCI-24: Mouse 
(C57BL/6 J Male) (Mus musculus) BAC library; BACPAC 
Resources, Oakland, CA, USA) using primers in Online 
resource 1 and inserted downstream of Renilla luciferase 
gene in pGL4.73[hRluc/SV40] vector (E6911, Promega, 
Madison, WI, USA) using restriction with XbaI. Lucif-
erase constructs containing BDNF 3′UTR with mutations 
in miR binding sites were generated with inverse PCR from 
the pGL4.73-BDNF3′UTR using primer pairs indicated in 
Online resource 1 (mutated nucleotides shown in bold). 
All constructs were verified by sequencing. Cotransfection 
with pGL4.13[luc2/SV40], encoding for firefly luciferase 
(E668A, Promega, Madison, WI, USA), was used for nor-
malization in the dual luciferase assay.
Cell culture
Human embryonic kidney 293 (HEK-293) cells were 
cultured at 37 °C with 5 % CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10 % fetal 
bovine serum (FBS; SV30160, Thermo Fisher Scientific, 
Waltham, MA, USA) and 1× Normocin (ant-nr-2, Invivo-
Gen, San Diego, CA, USA).
Human retinal pigment epithelium 19 (ARPE-19, [17]) 
cells were cultured at 37 °C with 5 % CO2 in DMEM/F-12 
(1:1) medium containing l-glutamine and 15 mM HEPES 
(31330, Invitrogen/Thermo Fisher Scientific, Waltham, MA, 
USA) supplemented with 10 % FBS and 1× Normocin.
Human primary glioblastoma U-87 MG cells were cul-
tured at 37 °C with 5 % CO2 in DMEM supplemented with 
10 % FBS and 1× Normocin. In all experiments, HEK-
293, ARPE-19 and U-87 MG cells were split 1:2 on two 
consecutive days prior to seeding.
C2C12 mouse skeletal myoblast cells [65] were main-
tained at subconfluent densities at 37 °C with 5 % CO2 in 
DMEM supplemented with 10 % FBS and 1× Normocin 
(growth medium, GM). Cells were kept at low density 
to prevent differentiation. Myogenic differentiation was 
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induced by replacing the growth medium with DMEM sup-
plemented with 2 % horse serum (HS; B15-021, PAA/GE 
Healthcare Life Sciences, Helsinki, Finland) and 1× Nor-
mocin (differentiation medium, DM).
Luciferase assay
For the luciferase assay, cells were seeded to a 96-well 
plate at a density of 15,000–20,000 cells/well in a final vol-
ume of 100 μl. After 24 h of incubation, 80–90 % conflu-
ent cells were transfected with 50 μl Opti-MEM I Reduced 
Serum Medium, GlutaMAX (51985, Gibco/Thermo 
Fisher Scientific, Waltham, MA, USA) containing 0.3 μl 
Lipofectamine 2000 Transfection Reagent (11668, 
Invitrogen/Thermo Fisher Scientific, Waltham, MA, USA), 
100 ng pGL4.73[hRluc/SV40] encoding for Renilla lucif-
erase with BDNF 3′UTR (BDNF-L), BDNF short 3′UTR 
(BDNF-SH) or mutated BDNF 3′UTR cloned downstream 
of the luciferase coding sequence, 10 ng pGL4.13 encod-
ing for firefly luciferase and 10 nM pre-miRs (where 
indicated, Applied Biosystems/Thermo Fisher Scientific, 
Waltham, MA, USA) per well. In experiments where miR 
binding site mutants were compared to each other, equi-
molar plasmid quantities were used. Cells were incubated 
for 3 h and transfection medium was replaced with 100 μl 
of fresh growth medium. Luciferase activity was measured 
after 24 h with Dual-Luciferase Reporter Assay System 
(Promega, Madison, WI, USA) as recommended by the 
manufacturer. Briefly, cells were lysed with 35 μl of Pas-
sive Lysis Buffer per well. Culture plate was incubated 
for 15 min with shaking at 400 rpm at room temperature. 
To record luminescence, 100 μl of Luciferase Assay Rea-
gent II was added to 30 μl of lysate for first measurement 
(firefly luciferase) and 100 μl of Stop & Glo Reagent was 
added for the second measurement (Renilla luciferase). 
Renilla/firefly luciferase ratio was used for statistical analy-
sis. Three to four replicate wells were used in each experi-
ment and experiments were repeated 3–5 times.
To assess the utilization of miR binding sites in the 
BDNF 3′UTR during myogenic differentiation, C2C12 
cells were seeded to a 96-well plate at a density of 10,000–
15,000 cells/well in a final volume of 100 μl. After 24 h of 
incubation, 40–50 % confluent cells were transfected with 
50 μl OptiMEM containing 0.3 μl Lipofectamine, 100 ng 
pGL4.73[hRluc/SV40] encoding for Renilla luciferase with 
BDNF 3′UTR or mutated BDNF 3′UTR cloned after the 
luciferase coding sequence and 10 ng pGL4.13 encoding 
for firefly luciferase per well. Cells were incubated for 3 h 
and transfection medium was replaced with 100 μl of fresh 
medium, either GM (to keep cells growing as undifferentiated 
myoblasts) or DM (to induce differentiation to myotubes). 
Luciferase activity in myoblasts was measured after 8 h. DM 
was replaced every day and luciferase activity in myotubes 
was measured after 4 days, as described above. Renilla/firefly 
luciferase ratio was used for statistical analysis. Three to four 
replicate wells were used in each experiment.
Transfection with pre-miRs
To quantify endogenous BDNF protein levels after treat-
ment with pre-miRs, ARPE-19 cells and U-87 MG cells 
were seeded to 6- or 12-well plates and incubated for 24 h 
to reach 90–100 % confluency. The medium was changed 
to GM and cells were transfected using OptiMEM con-
taining 5 μl (2.5 μl for 12-well plate) Lipofectamine 
and 100 nM pre-miRs per well in a final volume of 1 ml 
(500 μl) for 4 h, then replaced with GM and cultured for 
48 h. All experiments were performed with at least two bio-
logical repeats.
Silencing endogenous miRs with anti-miRs
To assess endogenous BDNF expression after silencing 
endogenous miRs, ARPE-19 and U-87 MG cells were seeded 
to 12-well plates at 90–100 % confluency. Medium was 
changed to 250 µl OptiMEM containing 6 µM Endoporter 
transfection agent, (GeneTools, LLC, Philomath, OR, USA) 
and 10 nM anti-miRs (Exicon, Vedbaek, Denmark) and cul-
tured for 24 h before substituting with 500 µl GM. Cells were 
cultured for 48 h before mRNA and protein isolation. All 
experiments were performed with two biological repeats.
BDNF enzyme-linked immunosorbent assay (ELISA)
Culture medium from cells treated with pre- or anti-miRs 
was centrifuged at 1,000 rpm to remove debris and used 
immediately for ELISA or stored at −80 °C. Cells were 
lysed with lysis buffer containing 137 mM NaCl, 20 mM 
Tris–HCl (pH 8.0), 1 % NP40, 10 % glycerol, 1 mM PMSF, 
10 μg/ml aprotinin, 1 μg/ml leupeptin and 0.5 mM sodium 
vanadate. Lysate was centrifuged for 20 min at 13,000 rpm 
at 4 °C and supernatant was used immediately or stored at 
−80 °C.
To assess BDNF expression in C2C12 myoblasts and 
myotubes during differentiation, C2C12 cells were seeded 
to a six-well plate in a density of 500,000 cells/well in 
1 ml of GM. After 24 h, culture medium was isolated from 
undifferentiated myoblasts and replaced with DM to induce 
differentiation. DM was changed daily and culture medium 
from myotubes was isolated on day four. Culture medium 
was centrifuged at 1,000 rpm and used immediately for 
BDNF ELISA.
Brain-derived neurotrophic factor ELISA was performed 
using BDNF Emax ImmunoAssay System (Promega, Madi-
son, WI, USA) as recommended by the manufacturer. Two 
replicates from each biological repeat were included in 
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ELISA. Brain-derived neurotrophic factor levels were nor-
malized to total protein concentration using DC Protein 
Assay (500-0116, Bio-Rad, Helsinki, Finland), as recom-
mended by the manufacturer.
RNA isolation
ARPE-19 and U-87 MG cells and hippocampi of C57BL/6 J 
mice were homogenized with TRI Reagent (TR 118, Molec-
ular Research Center, Inc., Cincinnati, OH, USA) and RNA 
was isolated as recommended by the manufacturer. Briefly, 
after incubation of the homogenate at room temperature 
for 5 min, 1-bromo-3-chloropropane (BP151, Molecular 
Research Center, Inc., Cincinnati, OH, USA) was added 
and the tubes were shaken vigorously for 15 s. The mix was 
incubated at room temperature for 5 min and centrifuged 
at 12,000 × g for 15 min at 4 °C. The aqueous phase was 
transferred to a fresh tube containing isopropanol (59300, 
Sigma-Aldrich, St. Louis, MO, USA), mixed by vortexing 
and incubated at room temperature for 10 min. Samples 
were centrifuged at 12,000 × g for 8 min at 4 °C and RNA 
pellet was washed with 70 % ethanol (Altia Oyi, Helsinki, 
Finland), followed by centrifugation at 7,500 × g for 5 min. 
Ethanol was then removed and the RNA pellet was allowed 
to briefly air dry and then dissolved in 30–50 μl H2O. 
The RNA samples were frozen immediately and stored at 
−80 °C until further processing. RNA quantity was meas-
ured with NanoDrop (Thermo Scientific, Waltham, MA, 
USA). The A260/A280 ratio was 1.78–2.01 and RNA yield 
was 3.5–9.5 μg (18–40 μg for hippocampus RNA).
Reverse transcription
RNA samples were treated with Turbo DNA-free DNase 
treatment and removal reagents, as recommended by 
the manufacturer (AM1907, Invitrogen/Thermo Fisher 
Scientific, Waltham, MA, USA), to prevent contamina-
tion with genomic DNA. cDNA was synthesized from 
150–500 ng of RNA (equal amount of RNA was used 
within a single experiment) with random hexamer primers 
in a final volume of 20 μl using Transcriptor First Strand 
cDNA synthesis kit as recommended by the manufacturer 
(04896866001, Roche, Basel, Switzerland). Briefly, 2 μl of 
random hexamer primers was mixed with 11 μl of RNA 
sample diluted with nuclease-free water, and incubated at 
65 °C for 10 min. Then 7 μl of mix containing 4 μl of 5× 
RT buffer, 2 μl of 100 mM dNTP, 0.5 μl of RNase inhibitor 
and 0.5 μl of Transcriptor reverse transcriptase was added, 
mixed gently, and incubated at 25 °C for 10 min, 55 °C for 
30 min, and 85 °C for 5 min. No reverse transcriptase con-
trol was included in each experiment. cDNA was cooled on 
ice, diluted 1:10, and stored at −20 °C or used immediately 
for qPCR.
Quantitative real-time PCR
Quantitative PCR reaction was performed with the Light-
Cycler 480 real-time PCR system (Roche Diagnostics, 
Basel, Switzerland) using LightCycler 480 SYBR Green 
I Master, complemented with 2.5 pmol of primers in the 
final volume of 10 μl on white 384-well plates sealed with 
adhesive plate sealer (04729749001, Roche, Basel, Swit-
zerland). An amount of 2.5 μl of the diluted cDNA product 
was used in each reaction. Oligonucleotide primers (Oli-
gomer Oy, Helsinki, Finland) used for the qPCR reactions 
are indicated in Online resource 1. No-reverse transcrip-
tion control and no-template control were included for each 
experiment. Two or three replicates of each reaction were 
included in the qPCR runs. The following qPCR program 
was used: [1] pre-incubation 10 min at 95 °C, [2] amplifica-
tion 10 s at 95 °C, 15 s at 60 °C, 15 s at 72 °C for 45 cycles, 
[3] melting curve 5 s at 95 °C, 30 s at 55 °C, continuous 
acquisition mode at 95 °C with two acquisitions per degree 
Celsius, and [4] cooling 10 s at 40 °C. The results were 
analyzed with LightCycler 480 Software Release 1.5.0 SP1 
using the Absolute Quantification/2nd Derivative Max cal-
culation. The quantification cycle (Cq) for the no-template 
control was 40 (or 0) in all experiments. Beta-actin was 
used as a reference gene. Results for a biological repeat 
were discarded when the Cq value for one or more of the 
replicates was 40 (or 0) or when the Cq difference between 
replicates was >1. For each primer pair, primer efficiencies 
(the ratio of amplified products if average Cq difference is 
one; the ideal efficiency would be two) were determined 
(Online resource 1). Fold difference to the reference gene 
was calculated according to the following formulation: 
FD = (E(GOI)−Cq1(GOI) + E(GOI)−Cq2(GOI))/(E−Cq1(ref)(ref) + E−Cq2(ref)(ref)), 
where EGOI and Eref are the primer efficiencies of the gene 
of interest (GOI) and reference gene (ref), respectively, and 
Cq1 and Cq2 are the Cq values of individual replicates.
microRNA expression
MicroRNA expression was assessed using TaqMan 
MicroRNA Assay reactions (Applied Biosystems/Thermo 
Fisher Scientific, Waltham, MA, USA) according to the 
manufacturer’s recommendations with minor modifica-
tions. Briefly, RNA was isolated as described above. 
cDNA from 0.3–1 μg RNA was synthesized with 
TaqMan MicroRNA Reverse Transcription Kit (Applied 
Biosystems/Thermo Fisher Scientific, Waltham, MA, 
USA) using Megaplex RT Primers, Rodent Pool A or B 
(Applied Biosystems/Thermo Fisher Scientific, Waltham, 
MA, USA) without preamplification in a final volume of 
7.5 μl. With the exception of miR-155 and miR-182, all 
the primers in the MegaPlex Rodent Pool were suitable 
for the amplification of human microRNAs. For miR-155 
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and miR-182, 5x RT primers provided by the TaqMan 
MicroRNA Assay were used for reverse transcription 
reaction. The cDNA product was diluted 1:30 and 2.5 μl 
of the diluted cDNA was used for each real-time PCR 
reaction in a final volume of 10 μl in 384-well plates. 
Each sample was run in duplicate. microRNA expression 
from mouse-derived cells was normalized to sno202 and 
microRNA expression from human-derived cells was nor-
malized to miR-191 [52].
Statistical analysis
All values are presented as mean ± SEM. Statistical sig-
nificance level was set at p < 0.05. Quantitative PCR data 
was calculated based on primer efficiencies and analyzed 
using fold difference compared to reference gene. Statisti-
cal analysis was performed using paired or unpaired Stu-
dent’s t test, Mann–Whitney U test, or one-way ANOVA 
followed by Tukey’s HSD (honestly significant difference) 
or Games–Howell post hoc analysis.
Results
Both BDNF 3′UTR isoforms are predicted to contain 
conserved binding sites for multiple miRs
We performed in silico analysis of BDNF 3′UTR-miR 
interactions using publicly available bioinformatics tool 
TargetScan (www.targetscan.org) and found that the 3′UTR 
of BDNF contains evolutionarily conserved seed sequences 
for multiple miRs (Fig. 1). In addition to miR sites, the 
overall nucleotide sequence of BDNF 3′UTR is highly 
conserved across species, especially near both ends of 
the 3′UTR (Fig. 1), suggesting important biological func-
tion of these regions. Most of the predicted miR binding 
sites fall into the 5′ end of the 3′UTR and the nucleotide 
sequences near miR sites are highly conserved across ver-
tebrates (Online resource 2). Brain-derived neurotrophic 
factor transcripts have either a long (BDNF-L, 2891 nt) or 
short (BDNF-SH, 350 nt) 3′UTR ([27], Fig. 1). Although in 
silico analysis with different target prediction tools, includ-
ing TargetScan ([43], http://www.targetscan.org), PITA 
([34], http://genie.weizmann.ac.il/pubs/mir07/index.html), 
miRanda ([33], http://www.microrna.org), PicTar ([38], 
http://pictar.mdc-berlin.de/) implies that BDNF 3′UTR can 
be regulated by a multitude of miRs (Online resource 3), to 
date only a few BDNF 3′UTR-miR interactions have been 
investigated, and in these, relatively short BDNF 3′UTR 
fragments have been used [25, 42, 46, 47]. Since there is 
potential for several miRs to bind BDNF 3′UTR, we set 
out to systematically investigate the role of ten miRs with 
conserved putative binding sites in BDNF 3′UTR isoforms 
in the regulation of BDNF expression. miRs of interest 
were selected based on the conservation of their binding 
site within BDNF 3′UTR, co-expression with BDNF in 
cells and tissues where BDNF is known to have important 
roles, and/or their overall expression level (Online resource 
2, microRNA.org, [20, 22, 31, 40]). We used full-length 
BDNF-L and BDNF-SH sequences to better preserve the 
potential effects that secondary structure and nucleotide 
context may have on miR binding.
Mus musculus BDNF 3'UTR
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590 bp 850 bp1030 bp
Fig. 1  Scheme of long (BDNF-L) and short (BDNF-SH) BDNF 
3′UTR isoforms with evolutionarily conserved miR sites predicted 
by TargetScan. Sites within BDNF-SH are shown in light blue. Con-
servation between mouse, rat, and human BDNF 3′UTR is shown in 
purple bars. Arrows denote polyadenylation sites
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Analysis of BDNF 3′UTR isoforms for miR regulation
We asked whether the in silico predicted miRs (Fig. 1) 
regulate protein synthesis from a transcript containing full-
length BDNF-L. For that, we transfected human embryonic 
kidney 293 (HEK-293) cells with precursors for ten miRs 
predicted by four different target prediction tools (Online 
resource 3) to bind BDNF-L (miR-1, miR-10b, miR-15a, 
miR-16, miR-30a, miR-30b, miR-155, miR-182, miR-191, 
and miR-195, Fig. 2a). Scrambled pre-miR (scr. miR) and 
precursor for miR-9 that do not have a strongly conserved 
predicted binding site in BDNF-L were used as negative 
controls. We found that miR-1, which has three binding 
sites in BDNF-L (Fig. 2a), reduces luciferase signal most 
efficiently (Fig. 2b). Of the other miRs, miR-10b, miR-
155, and miR-191 significantly inhibited luciferase signal 
compared to the scrambled miR control. Unlike in previous 
studies, which utilized fragments of BDNF 3′UTR in the 
same reporter assay, we found no significant effect for 
miR-30a or miR-195 (Fig. 2b).
In parallel, we tested the ability of the same miRs to 
inhibit protein synthesis from transcript containing BDNF-
SH, which contains binding sites for six miRs out of the 
ten assessed in BDNF-L (Fig. 2a, c). We found that miR-1 
and miR-10b significantly reduced luciferase activity. Of 
the three miR-1 sites present in BDNF-L, only the first is 
located within BDNF-SH (Fig. 2a, c). If miR-1 sites act 
additively to regulate BDNF levels, miR-1 is expected 
to have a milder effect on a reporter construct carrying 
BDNF-SH compared to BDNF-L. Matching the prediction, 
we found a statistically significant difference in the extent 
of luciferase signal reduction by miR-1 on BDNF-SH com-
pared to BDNF-L (Fig. 2b). Similarly, unlike BDNF-L, 













































































































BDNF-L and BDNF-SH luciferase reporter assay with pre-miRs
miR sites in BDNF-L and BDNF-SH Number of miR sites
Fig. 2  Several of the predicted miRs regulate BDNF 3′UTR. a 
Scheme of miR sites within BDNF-L and BDNF-SH. Only miRs 
included in the current study are shown. Arrows denote polyade-
nylation sites. b Luciferase activity of reporter constructs contain-
ing either BDNF-L or BDNF-SH, co-transfected with pre-miRs. 
Dark grey bars show inhibition of BDNF-L by miRs and light grey 
bars show inhibition of BDNF-SH by miRs. # indicates differ-
ence from treatment with negative control and * indicates differ-
ences between the extent of miR inhibition between BDNF-L and 
BDNF-SH. n = 3–8, #p < 0.05, ###p < 0.001, *p < 0.05, **p < 0.01, 
***p < 0.001. c Number of miR sites in BDNF-L and BDNF-SH pre-
dicted by TargetScan. miRs that have a different number of predicted 
binding sites within BDNF-L and BDNF-SH are shown in bold
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As expected, miR-155 and miR-191 had no effect on 
BDNF-SH, while they had a significant effect on BDNF-
L (Fig. 2b). Thus, we found a statistically significant dif-
ference in the extent of luciferase signal reduction between 
BDNF-L and BDNF-SH by miR-1, miR-155 and miR-191 
that have a different number of predicted binding sites in 
the long and short BDNF 3′UTR isoforms. In contrast, 
there was no difference in luciferase activity after treatment 
with miR-10b that has a single binding site predicted to 
regulate both BDNF-L and BDNF-SH (Fig. 2a–c). These 
data suggest that miR-1, miR-10b, miR-155, and miR-191 
are novel regulators of BDNF 3′UTR and that a subset of 
them are able to differentially regulate expression from 
transcripts containing either short or long 3′UTR isoform.
Regulation of endogenous BDNF levels by miRs
Next, we asked if the miRs that regulate BDNF 3′UTR 
in a reporter assay can also regulate endogenous BDNF. 
Towards that end, we made use of human retinal pigment 
epithelial (ARPE-19) cells and human glioblastoma cell-
line U-87 MG that secrete a detectable amount of endog-
enous BDNF. Relative expression of BDNF and BDNF-
regulated miRs in different cell lines used in this study is 
shown in Online resource 4a and 5. We found that approxi-
mately 80 % of BDNF mRNA transcripts in ARPE-19 
cells and 95 % of BDNF transcripts in U-87 MG cells are 
expressed as short 3′UTR isoforms (Fig. 3a), suggesting 
that miR-155 and miR-191, which only have a binding site 
within BDNF-L, should be unable to regulate the majority 
of BDNF transcripts in these cells (Fig. 2a). We transfected 
ARPE-19 cells with precursors for miR-1, miR-10b, miR-
155, and miR-191, and measured BDNF mRNA levels with 
primers recognizing total BDNF and BDNF transcript car-
rying the long 3′UTR (BDNF-L). miR-10b significantly 
decreased both total BDNF and BDNF-L levels, while 
miR-155 and miR-191 only reduced BDNF-L expression, 
as expected (Fig. 3b–c). We then determined BDNF pro-
tein levels in the cell lysate and culture medium by ELISA. 
We found that miR-1 and miR-10b effectively suppressed 
endogenous BDNF synthesis, while miR-155 and miR-
191 did not significantly reduce BDNF levels (Fig. 3d–e). 
Brain-derived neurotrophic factor levels in the culture 
medium were decreased more compared to the whole cell 
lysate, indicating that in addition to BDNF, miR-1 and 
miR-10b could regulate the expression of proteins involved 
in BDNF secretion. Surprisingly, although BDNF mRNA 
levels were increased by transfection with miR-1, pro-
tein levels were decreased (Fig. 3b–e), suggesting that the 
mechanism by which miR-1 suppresses BDNF may be dif-
ferent from that of other miRs and may involve other fac-
tors that regulate BDNF expression. Taken together, these 
data suggest that miR-1 and miR-10b inhibit endogenous 
BDNF levels but do not exclude the ability of miR-155 and 
miR-191 to do the same in cells expressing BDNF tran-
script with the long 3′UTR isoform.
Since BDNF has multiple functions in the central nerv-
ous system, we also tested pre-miRs in U-87 MG glioblas-
toma cells that originate from the CNS. However, only 5 % 
of BDNF transcripts in these cells carry the long 3′UTR 
isoform (Fig. 3a). We found that while total BDNF lev-
els were not reduced after treatment with any of the pre-
miRs, the expression of BDNF transcripts carrying the 
long 3′UTR was significantly decreased by about 20 % by 
all the pre-miRs tested (Fig. 3f–g). Interestingly, although 
miR-1 and miR-10b have a binding site within BDNF-SH 
and should therefore be able to regulate the expression of 
all BDNF transcripts, they seem to be effective only in sup-
pressing BDNF-L in U-87 MG cells (Fig. 3f–g). Consistent 
with our finding that miRs only regulate a marginal sub-
population of BDNF transcripts, resulting in about 20 % 
decrease in BDNF-L levels, BDNF protein levels in U-87 
MG cells were not suppressed by transfection with pre-
miRs (Fig. 3h–i).
Finally, we transfected ARPE-19 cells with anti-miR-10 
and found that silencing endogenous miR-10b significantly 
increased BDNF mRNA and protein levels (Fig. 3j–m). 
We were unable to address the effect of miR-1 in ARPE-
19 cells, since it is not expressed in this cell line (Online 
resource 5). In summary, our results suggest that miR-
1, miR-10b, miR-155, and miR-191 are able to regulate 
BDNF expression, although the effect may vary depending 
on the cell line.
miR-1, miR-10b, miR-155, and miR-191 regulate BDNF 
3′UTR directly through their predicted sites
Quantifying endogenous BDNF expression after treatment 
with pre- or anti-miRs does not allow to distinguish whether 
miRs regulate BDNF levels directly or indirectly. To inves-
tigate the interaction between the miRs identified to sup-
press BDNF-L (Fig. 2b) and their concomitant binding sites 
within the BDNF 3′UTR, we created constructs harboring 
mutations in one or several miR binding sites in BDNF-L 
(Fig. 4a–b). Since miR-1 has three predicted sites, we gen-
erated mutant constructs for each of the sites individually 
(miR1-1m, miR1-2/191m, miR1-3m) and a triple mutant 
with all three binding sites mutated (miR1m). It should be 
noted that the second binding site of miR-1 (miR-1-2) partly 
overlaps with miR-191 binding site and therefore both 
sites were mutated in miR-1-2 mutant (Fig. 4a–b). We co-
transfected mutant constructs with the corresponding pre-
miRs into HEK-293 cells as above and assessed the relative 
extent of inhibition. In accordance with analysis of BDNF-
L vs. BDNF-SH (Fig. 2b), mutating the first site (miR1-
1m), which is also present within BDNF-SH, reduced 
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suppression by miR-1 most effectively compared to mutat-
ing the other miR-1 sites (Fig. 4c), suggesting that miR-
1-1 site is more important in regulating BDNF 3′UTR than 
miR-1-2 and miR-1-3 sites. Furthermore, mutating the third 
miR-1 site (miR1-3m) did not change 3′UTR inhibition by 
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be used by miR-1 for suppression of BDNF 3′UTR. Mutat-
ing miR-10b (miR10m), miR-155 (miR155m), and miR-
191 (miR1-2/191m) sites effectively abolished the inhibi-
tory effect of the corresponding exogenous miRs (Fig. 4d), 
suggesting that these miRs also directly inhibit protein syn-
thesis by binding to the predicted site in the BDNF 3′UTR.
miR-1/206 sites in BDNF 3′UTR are used by endogenous 
miRs in differentiated but not in undifferentiated muscle 
cells
Regulation of BDNF expression has been shown to be 
required for postnatal growth and repair of skeletal muscle 
in vivo [13]. To gain further insight into the physiological 
relevance of miR sites identified to regulate BDNF 3′UTR, 
we extended our analysis to a model of muscle differentia-
tion, the mouse myoblast C2C12 cells, where reduction in 
BDNF levels is believed to be required to allow myotube 
generation from undifferentiated myoblasts [47]. miR-206, 
a miR-1/206 microRNA family member that has identi-
cal seed sequence to miR-1 but differs from miR-1 by four 
nucleotides (Online resource 4b), is believed to be involved 
in BDNF downregulation in C2C12 cells [47]. However, it 
is unknown whether the predicted miR-1/206 sites are the 
sites used by endogenous miR-1 and/or miR-206 during 
muscle differentiation. Furthermore, it has remained unclear 
if BDNF suppression by miR-1/206 is used in myoblasts to 
induce differentiation, in myotubes to maintain differentia-
tion, or both. To gain further insight into these questions, we 
first confirmed earlier findings that BDNF is downregulated 
with concurrent upregulation of miR-1 and miR-206 upon 
myogenic differentiation of muscle cells (Online resource 
4c–e; [12, 35, 47, 49]). Then we analyzed the effect of 
miR-1/206 site mutations on reporter construct expression 
in myoblasts and myotubes. We found that BDNF-L was 
repressed in differentiated myotubes by about 50 %, while 
miR1m mutant construct was not (Fig. 5a). Furthermore, 
although both miR-1 and miR-206 are expressed in myo-
blasts (Online resource 4e, 5), there was no difference in the 
expression of BDNF-L and miR1m containing reporters in 
those cells (Fig. 5a). This suggests that interaction between 
BDNF 3′UTR and miR-1/206 family miRs is utilized in 
C2C12 myotubes to maintain differentiation by BDNF 
repression but not to induce myogenic differentiation.
Endogenous miRs regulate BDNF 3′UTR in different cell 
lines through the predicted sites
Next we turned to cell lines where interaction between 
BDNF 3′UTR and endogenous miRs has not been addressed 
before. We determined the endogenous miR expression 
levels in human embryonic kidney cell line HEK-293 and 
human retinal pigment epithelial cell line ARPE-19. We 
found that miR-1 was not expressed in ARPE-19 cells and 
miR-155 was not expressed in HEK-293 cells, while the 
other miRs were expressed but their relative levels were 
different between HEK-293 and ARPE-19 cells (Online 
resource 5). To assess the interaction between BDNF 3′UTR 
and endogenous miRs, we transfected HEK-293 and ARPE-
19 cells with luciferase assay reporter containing native 
BDNF-L or constructs harboring various miR site mutants: 
mutations for each individual miR-1 site (miR1-1m, miR1-
2/191m, miR1-3m), all three miR-1 binding sites (miR1m), 
miR-10b site (miR10m), miR-155 site (miR155m) and a 
quadruple mutant for three miR-1 sites and miR-10b site 
(miR1,10m). As indicated above, miR-191 site was mutated 
in miR1-2/191m mutant construct (Fig. 4b). We found that 
mutating miR-10b site significantly derepressed luciferase 
construct in both cell lines (Fig. 5b–c). Consistent with our 
findings with miR-1 transfection (Fig. 4c), we found that 
mutating the miR-1-1 site, but not the other miR-1 sites 
increased luciferase signal in HEK-293 cells (Fig. 5c). In 
ARPE-19 cells, luciferase signal obtained with the quadru-
ple mutant miR1,10m was increased by approximately two-
fold compared to wild-type BDNF-L. However, in HEK-
293 cells, mutating all three sites for miR-1 and the single 
miR-10b site (miR1,10m) derepressed luciferase activity to 
the level comparable to the empty luciferase vector carrying 
SV40 late 3′UTR (Fig. 5c), which is in essence devoid of 
binding sites for strongly conserved miRs (Online resource 
6). These results indicate that miR-1 and miR-10 sites within 
BDNF 3′UTR are used synergistically by endogenous miR-
1/206 and miR-10 family miRs to repress BDNF 3′UTR, and 
at least in HEK-293 cells miR-1/206 and miR-10 sites are 
responsible for the majority of BDNF 3′UTR repression.
Discussion
Here we present the first systematic functional analysis 
of nine evolutionarily conserved miR recognition sites in 
BDNF 3′UTR. Unlike previous studies, we have analyzed 
full-length sequences of both BDNF 3′UTR isoforms, 
BDNF-L (2891 nt) and BDNF-SH (350 nt). We identify 
Fig. 3  Regulation of endogenous BDNF levels by pre- and anti-
miRs. a Expression of BDNF-L and BDNF-SH mRNA isoforms in 
ARPE-19 and U-87 MG cells. Endogenous BDNF levels in ARPE-
19 (b–e) and U-87 MG (f–i) cells transfected with pre-miRs, relative 
to scrambled control. j–m Endogenous BDNF levels in ARPE-19 
cells transfected with anti-miRs, relative to scrambled control. b, f, j 
Total BDNF mRNA levels, normalized to β-actin. c, g, k mRNA lev-
els of BDNF transcripts containing the long 3′UTR (BDNF-L), nor-
malized to β-actin. d, h, l BDNF protein levels in whole cell lysate, 
normalized to total protein content. e, i, m BDNF protein levels in 
culture medium, normalized to total protein content. n = 3. Aster-
isks show difference from negative control, *p < 0.05, **p < 0.01, 
***p < 0.001. Error bars denote mean ± SEM
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Scheme of miR site mutations in BDNF-L Mutated miR binding site sequences in BDNF-L
Luciferase assay 
with miR-1 mutants
Luciferase assay with miR-10, 
miR-155 and miR-191 mutants
Fig. 4  Regulation of luciferase signal by miRs is specific to the pre-
dicted miR binding sites. a Schemes of miR site mutations in BDNF-
L. Mutated sites are shown for each BDNF-L mutant. Arrows denote 
polyadenylation sites. b miR binding site mutations in BDNF-L. 
BDNF 3′UTR sequences complementary to miR seed sites are indi-
cated with brackets. Mutated nucleotides are shown in bold. c Mutat-
ing miR-1 predicted binding sites in BDNF-L prevents repression 
by miR-1 in a luciferase reporter assay in HEK-293 cells. n = 3. d 
Mutating miR-10b, miR-155, and miR-191 predicted binding sites 
prevents repression by the respective miRs in a luciferase reporter 
assay in HEK-293 cells. n = 3. c, d Reporter expression is shown 
relative to scrambled pre-miR. Error bars denote mean ± SEM. 
Asterisks show difference from BDNF-L; *p < 0.05, **p < 0.01, 
***p < 0.001
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miR-1, miR-10b, miR-155, and miR-191 as novel regulators 
of BDNF 3′UTR and show that BDNF-L and BDNF-SH 
can be differentially regulated by a subset of miRs. Using 
mutated constructs we show that the interaction between the 
identified miRs and BDNF 3′UTR is direct. Our results sug-
gest that miR-1/206 sites within BDNF 3′UTR are used in 
C2C12 myotubes to maintain differentiation rather than in 
myoblasts to induce differentiation. Finally, we show that 
the predicted binding sites for miR-1/206 and miR-10 fam-
ily miRs are used in a synergistic manner to repress BDNF 
3′UTR in ARPE-19 and HEK-293 cells.
The potential physiological importance of BDNF regu-
lation by miRs has been suggested by a study where Dicer, 
an enzyme required for miR maturation, was conditionally 
deleted from the forebrain. Prior to the onset of neurode-
generation, BDNF levels in such animals were increased 
with concomitant functional changes in the CNS [36]. 
Recently, the conclusion was confirmed by Lee et al., who 
demonstrated BDNF regulation by miR-206 in the brain 
[42]. In addition, other studies have addressed the poten-
tial interaction between BDNF 3′UTR and specific miRs. 
Interestingly, miR-30a and miR-195 did not have an effect 
in our study (Fig. 2b) while previous results have suggested 
that these miRs regulate BDNF 3′UTR in a reporter assay 
[46]. These different results can at least partly be explained 
by the use of 3′UTR fragments in the reporter assay of the 
previous study, which may affect the accessibility of miRs 
to their binding site in the target mRNA. It has been shown 
that miR sites residing near the two ends of long 3′UTRs 
are generally more effective than those near the center 
[29]. Thus, a site normally unavailable in the native 3′UTR 
may become more accessible if only a small region of the 
3′UTR is analyzed in reporter assay and in some cases, 
the situation may be the other way around. miR-191 has 
been shown not to inhibit BDNF 3′UTR [46], whereas 
our results clearly show that miR-191 does in fact directly 
inhibit BDNF 3′UTR via the predicted site (Fig. 2b, 4d).
Further illustrating the potential problems stemming 
from analysis of fragments rather than full-length 3′UTRs 
are the conflicting results of studies by Miura et al. and Lee 
et al. [42, 47], where the first study showed that of three 
miR-206 sites within BDNF 3′UTR, the first two and not 
the third are functional, while the other study reached the 
opposite conclusion. Although both studies analyzed frag-
ments of BDNF 3′UTR, the size of fragments used in [47] 
was longer than those studied in [42] and thus resembled 
the full-length BDNF 3′UTR better. Our analysis of full-
length BDNF 3′UTR interaction with miR-1, another fam-
ily member of miR-1/206 family, supports the conclusion of 
(Fig. 2b, 4c, [47]). Our data on miR-1 also confirms the in 
silico prediction that miR-1 and miR-206 share the binding 
sites on BDNF 3′UTR (Fig. 1). However, it is important to 
keep in mind that miR-1 and miR-206 differ by four nucleo-
tides outside the seed sequence (Online resource 4b). There-
fore, it would be interesting to analyze miR-206 and BDNF 
3′UTR interaction in the context of full-length 3′UTR.
We also found that endogenous miR-1/206 and miR-10 
family miRs act cooperatively to repress BDNF expres-
sion through its 3′UTR in two cell lines of different origin 
(Fig. 5b–c). This is consistent with the notion from previ-
ous reports that multiple miR sites within a 3′UTR can act 






































































































































































Reporter assay in C2C12 
myoblasts and myotubes
Reporter assay with miR site 
mutants in ARPE-19 cells
Reporter assay with miR site 
mutants in HEK-293 cells
Fig. 5  Mutating miR-1 and miR-10 sites abolishes suppression of 
BDNF-L by endogenous miRs in a reporter assay. a Reporter activ-
ity in C2C12 cells before and after differentiation with constructs 
containing either wild-type BDNF-L or BDNF-L miR site mutants. 
n = 7. b, c Luciferase activity of reporter constructs containing wild-
type BDNF-L or BDNF-L miR site mutants. Asterisks show differ-
ence from BDNF-L. n = 3–4. b Luciferase activity in ARPE-19 cells. 
c Luciferase activity in HEK-293 cells. n = 3–5. Error bars denote 
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001
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close together [29, 56, 57]. In line with this, recent experi-
mental evidence shows that noncoding pseudogenes can 
bind to and compete for the same combination of miRs as 
their ancestral gene [53], suggesting that there has been 
evolutionary pressure on pseudogenes to preserve the same 
miR binding site pattern or “miR code” that is used to reg-
ulate protein synthesis from the ancestral transcript. Even 
though the expression levels of pseudogenes are low, they 
seem to be sufficient to derepress endogenous parent gene 
expression in case their 3′UTR contains binding sites for 
multiple miRs that act in synergy. Our data imply that regu-
lation of BDNF by its 3′UTR is important in tissues where 
miR-1/206 and miR-10 family miRs are co-expressed. In 
addition, although mutating miR-155 and miR-191 sites 
had no effect on reporter activity in HEK-293 and ARPE-
19 cells, it cannot be excluded that BDNF 3′UTR interacts 
with miR-155 or miR-191 in other tissues or cell types.
Although some studies have suggested that inhibition 
by miRs depends mostly on miR expression levels [18, 
28], others suggest that additional factors such as specific 
nucleotide composition [53, 57], or the number of target 
genes [4] may be more important in defining the repressive 
activity of miRs. Our results indicate that endogenous miR 
expression levels do not solely determine the inhibition 
efficiency. In assays utilizing reporter constructs and pre-
miR transient transfection, miR-1 through its sites 1 and 2, 
miR-10b and miR-191 all suppress BDNF 3′UTR (Fig. 2b, 
4c–d). However, despite the presence of relatively high 
levels of endogenous miR-191 compared to endogenous 
miR-1 and miR-10b in both HEK-293 and ARPE-19 cells 
(Online resource 5), mutating miR-191 site did not lead to 
an increase in luciferase signal, whereas mutating miR-10b 
site or miR-1 sites together with miR-10b site had a clear 
effect (Fig. 5b–c). Thus, results suggesting direct interac-
tion between miR and 3′UTR in transient transfection 
assays do not allow conclusions on the interaction between 
endogenous miR and the corresponding site within the 
3′UTR, even if the endogenous miR expression levels are 
high, underlining the need to test each case separately.
While the role of miR-1/206 family member miR-206 in 
the regulation of BDNF levels is well established [42, 47, 
54], the interaction between BDNF 3′UTR and miR-1 has 
not been investigated. Although miR-1 and miR-206 have 
identical seed sequences, the mature miR-1 differs from 
miR-206 by four nucleotides (Online resource 4b). miR-1 
is encoded by two distinct genomic locations in both mouse 
and human genomes and displays partially different expres-
sion pattern from miR-206. For example, both miR-1 and 
miR-206 are expressed in high levels in the skeletal mus-
cle [12, 35, 39, 59, 68], but unlike miR-206, miR-1 lev-
els are high in the heart [40]. Since BDNF is known to be 
required for heart angiogenesis [16], it would be interest-
ing to assess the role of miR-1 and BDNF interaction in 
heart development. Moreover, appropriate BDNF levels are 
important for adjusting the number of dopaminergic neu-
rons in the substantia nigra midbrain [5] and regulation 
of BDNF expression in the hippocampus is important in 
learning and memory (see [64]). miR-1 is expressed within 
the midbrain [40], hippocampus (Online resource 5), and 
in several other neuron populations within the central nerv-
ous system [30]. Taken together, there is potential for miR-
1-mediated regulation of BDNF levels during development, 
warranting further investigation.
While miR-191 is widely expressed in different tis-
sues and cell types, miR-10b and miR-155 have a more 
restricted expression pattern [40]. For example, one of the 
few expression sites of miR-10b is the skin [40], whereas 
expression of BDNF in the skin is required for its proper 
sensory innervation [21]. miR-155, on the other hand, is 
robustly upregulated after the activation of immune cells, 
including microglia [9], whereas BDNF expression by 
microglia has been implicated in the induction of neuro-
pathic pain [14, 66].
Our results also suggest that selected miRs are able to 
differentially regulate BDNF transcripts with either long or 
short 3′UTR isoform. Indeed, the considerably shorter half-
life of BDNF mRNAs containing the long 3′UTR compared 
to the short 3′UTR [10] may at least partly be a consequence 
of miR regulation. Furthermore, the relative abundance of 
BDNF 3′UTR isoforms varies during developmental pro-
cesses, for example, in muscle differentiation [47], and 
in different brain areas, such as the cortex, hippocampus 
and cerebellum [3, 62], suggesting that the long and short 
3′UTR isoforms have different biological functions. In line 
with this, it was recently shown that in response to neuronal 
activation, BDNF protein synthesis in hippocampal neu-
rons is rapidly initiated from transcripts containing the long 
3′UTR, while expression from transcripts containing the 
short 3′UTR maintains basal BDNF levels [41].
Overall, co-expression of BDNF and miR-1/miR-10b/
miR-155/miR-191 in various cell types and tissues suggests 
potential relevance of the interaction between miRs and 
BDNF 3′UTR isoforms in different physiological and path-
ological processes, which remain a target of future studies 
addressing post-transcriptional BDNF regulation.
Acknowledgments This work was supported by the Academy of 
Finland [136591, 140983, and 263700] and Institute of Biotechnology 
(to J.O.A), the Doctoral Program Brain & Mind (to K.V.) and Hel-
sinki Graduate Program in Biotechnology and Molecular Biology (to 
A.K). JOA declares that one patent application is pending regarding 
the reported findings. The authors thank Urmas Arumäe, Eero Castrén 
and Kert Mätlik for comments on the manuscript.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
4455miR-1, miR-10b, miR-155, and miR-191
1 3
References
 1. Abidin I, Eysel UT, Lessmann V, Mittmann T (2008) Impaired 
GABAergic inhibition in the visual cortex of brain-derived 
neurotrophic factor heterozygous knockout mice. J Physiol 
586:1885–1901
 2. Abidin I, Kohler T, Weiler E, Zoidl G, Eysel UT, Lessmann V, 
Mittmann T (2006) Reduced presynaptic efficiency of excitatory 
synaptic transmission impairs LTP in the visual cortex of BDNF-
heterozygous mice. Eur J Neurosci 24:3519–3531
 3. An JJ, Gharami K, Liao GY, Woo NH, Lau AG, Vanevski F, Torre 
ER, Jones KR, Feng Y, Lu B, Xu B (2008) Distinct role of long 3′ 
UTR BDNF mRNA in spine morphology and synaptic plasticity 
in hippocampal neurons. Cell 134:175–187
 4. Arvey A, Larsson E, Sander C, Leslie CS, Marks DS (2010) Tar-
get mRNA abundance dilutes microRNA and siRNA activity. 
Mol Syst Biol 6:363
 5. Baquet ZC, Bickford PC, Jones KR (2005) Brain-derived neuro-
trophic factor is required for the establishment of the proper num-
ber of dopaminergic neurons in the substantia nigra pars com-
pacta. J Neurosci 25:6251–6259
 6. Barrett LW, Fletcher S, Wilton SD (2012) Regulation of eukary-
otic gene expression by the untranslated gene regions and other 
non-coding elements. Cell Mol Life Sci 69:3613–3634
 7. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mecha-
nism, and function. Cell 116:281–297
 8. Calabrese F, Molteni R, Maj PF, Cattaneo A, Gennarelli M, Raca-
gni G, Riva MA (2007) Chronic duloxetine treatment induces 
specific changes in the expression of BDNF transcripts and in the 
subcellular localization of the neurotrophin protein. Neuropsy-
chopharmacology 32:2351–2359
 9. Cardoso AL, Guedes JR, Pereira de Almeida L, Pedroso de Lima 
MC (2012) miR-155 modulates microglia-mediated immune 
response by down-regulating SOCS-1 and promoting cytokine 
and nitric oxide production. Immunology 135:73–88
 10. Castren E, Berninger B, Leingartner A, Lindholm D (1998) Reg-
ulation of brain-derived neurotrophic factor mRNA levels in hip-
pocampus by neuronal activity. Prog Brain Res 117:57–64
 11. Chan JP, Unger TJ, Byrnes J, Rios M (2006) Examination of 
behavioral deficits triggered by targeting Bdnf in fetal or postna-
tal brains of mice. Neuroscience 142:49–58
 12. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond 
SM, Conlon FL, Wang DZ (2006) The role of microRNA-1 and 
microRNA-133 in skeletal muscle proliferation and differentia-
tion. Nat Genet 38:228–233
 13. Clow C, Jasmin BJ (2010) Brain-derived neurotrophic factor reg-
ulates satellite cell differentiation and skeletal muscle regenera-
tion. Mol Biol Cell 21:2182–2190
 14. Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, 
Gravel C, Salter MW, De Koninck Y (2005) BDNF from micro-
glia causes the shift in neuronal anion gradient underlying neuro-
pathic pain. Nature 438:1017–1021
 15. Dluzen DE, Anderson LI, McDermott JL, Kucera J, Walro JM 
(2002) Striatal dopamine output is compromised within ± BDNF 
mice. Synapse 43:112–117
 16. Donovan MJ, Lin MI, Wiegn P, Ringstedt T, Kraemer R, Hahn R, 
Wang S, Ibanez CF, Rafii S, Hempstead BL (2000) Brain derived 
neurotrophic factor is an endothelial cell survival factor required for 
intramyocardial vessel stabilization. Development 127:4531–4540
 17. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM (1996) 
ARPE-19, a human retinal pigment epithelial cell line with dif-
ferentiated properties. Exp Eye Res 62:155–169
 18. Ebert MS, Neilson JR, Sharp PA (2007) MicroRNA sponges: 
competitive inhibitors of small RNAs in mammalian cells. Nat 
Methods 4:721–726
 19. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana 
BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu 
B, Weinberger DR (2003) The BDNF val66met polymorphism 
affects activity-dependent secretion of BDNF and human mem-
ory and hippocampal function. Cell 112:257–269
 20. Ernfors P, Ibanez CF, Ebendal T, Olson L, Persson H (1990) 
Molecular cloning and neurotrophic activities of a protein with 
structural similarities to nerve growth factor: developmental and 
topographical expression in the brain. Proc Natl Acad Sci USA 
87:5454–5458
 21. Ernfors P, Lee KF, Jaenisch R (1994) Mice lacking brain-
derived neurotrophic factor develop with sensory deficits. Nature 
368:147–150
 22. Ernfors P, Wetmore C, Olson L, Persson H (1990) Identification 
of cells in rat brain and peripheral tissues expressing mRNA for 
members of the nerve growth factor family. Neuron 5:511–526
 23. Ferrer I, Goutan E, Marin C, Rey MJ, Ribalta T (2000) Brain-
derived neurotrophic factor in Huntington disease. Brain Res 
866:257–261
 24. Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mecha-
nisms of post-transcriptional regulation by microRNAs: are the 
answers in sight? Nat Rev Genet 9:102–114
 25. Friedman LM, Dror AA, Mor E, Tenne T, Toren G, Satoh T, 
Biesemeier DJ, Shomron N, Fekete DM, Hornstein E, Avraham 
KB (2009) MicroRNAs are essential for development and func-
tion of inner ear hair cells in vertebrates. Proc Natl Acad Sci USA 
106:7915–7920
 26. Fukuchi M, Tsuda M (2010) Involvement of the 3′-untranslated 
region of the brain-derived neurotrophic factor gene in activity-
dependent mRNA stabilization. J Neurochem 115:1222–1233
 27. Funakoshi H, Frisen J, Barbany G, Timmusk T, Zachrisson O, 
Verge VM, Persson H (1993) Differential expression of mRNAs 
for neurotrophins and their receptors after axotomy of the sciatic 
nerve. J Cell Biol 123:455–465
 28. Gentner B, Schira G, Giustacchini A, Amendola M, Brown BD, 
Ponzoni M, Naldini L (2009) Stable knockdown of microRNA in 
vivo by lentiviral vectors. Nat Methods 6:63–66
 29. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, 
Bartel DP (2007) MicroRNA targeting specificity in mammals: 
determinants beyond seed pairing. Mol Cell 27:91–105
 30. He M, Liu Y, Wang X, Zhang MQ, Hannon GJ, Huang ZJ (2012) 
Cell-type-based analysis of microRNA profiles in the mouse 
brain. Neuron 73:35–48
 31. Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA (1990) 
Regional distribution of brain-derived neurotrophic factor mRNA 
in the adult mouse brain. EMBO J 9:2459–2464
 32. Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal 
development and function. Annu Rev Neurosci 24:677–736
 33. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS 
(2004) Human MicroRNA targets. PLoS Biol 2:e363
 34. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E (2007) The 
role of site accessibility in microRNA target recognition. Nat 
Genet 39:1278–1284
 35. Kim HK, Lee YS, Sivaprasad U, Malhotra A, Dutta A (2006) 
Muscle-specific microRNA miR-206 promotes muscle differen-
tiation. J Cell Biol 174:677–687
 36. Konopka W, Kiryk A, Novak M, Herwerth M, Parkitna JR, Waw-
rzyniak M, Kowarsch A, Michaluk P, Dzwonek J, Arnsperger T, 
Wilczynski G, Merkenschlager M, Theis FJ, Kohr G, Kaczmarek 
L, Schutz G (2010) MicroRNA loss enhances learning and mem-
ory in mice. J Neurosci 30:14835–14842
 37. Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T 
(1995) Hippocampal long-term potentiation is impaired in mice 
lacking brain-derived neurotrophic factor. Proc Natl Acad Sci 
USA 92:8856–8860
4456 K. Varendi et al.
1 3
 38. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, 
MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky 
N (2005) Combinatorial microRNA target predictions. Nat Genet 
37:495–500
 39. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, 
Tuschl T (2002) Identification of tissue-specific microRNAs from 
mouse. Curr Biol 12:735–739
 40. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, 
Pfeffer S, Rice A, Kamphorst AO, Landthaler M, Lin C, Socci 
ND, Hermida L, Fulci V, Chiaretti S, Foa R, Schliwka J, Fuchs U, 
Novosel A, Muller RU, Schermer B, Bissels U, Inman J, Phan Q, 
Chien M, Weir DB, Choksi R, De Vita G, Frezzetti D, Trompeter 
HI, Hornung V, Teng G, Hartmann G, Palkovits M, Di Lauro 
R, Wernet P, Macino G, Rogler CE, Nagle JW, Ju J, Papavasil-
iou FN, Benzing T, Lichter P, Tam W, Brownstein MJ, Bosio A, 
Borkhardt A, Russo JJ, Sander C, Zavolan M, Tuschl T (2007) 
A mammalian microRNA expression atlas based on small RNA 
library sequencing. Cell 129:1401–1414
 41. Lau AG, Irier HA, Gu J, Tian D, Ku L, Liu G, Xia M, Fritsch B, 
Zheng JQ, Dingledine R, Xu B, Lu B, Feng Y (2010) Distinct 
3′UTRs differentially regulate activity-dependent translation of 
brain-derived neurotrophic factor (BDNF). Proc Natl Acad Sci 
USA 107:15945–15950
 42. Lee ST, Chu K, Jung KH, Kim JH, Huh JY, Yoon H, Park DK, 
Lim JY, Kim JM, Jeon D, Ryu H, Lee SK, Kim M, Roh JK 
(2012) miR-206 regulates brain-derived neurotrophic factor in 
Alzheimer disease model. Ann Neurol 72:269–277
 43. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, 
often flanked by adenosines, indicates that thousands of human 
genes are microRNA targets. Cell 120:15–20
 44. Lu B (2003) BDNF and activity-dependent synaptic modulation. 
Learn Mem 10:86–98
 45. Lyons WE, Mamounas LA, Ricaurte GA, Coppola V, Reid SW, 
Bora SH, Wihler C, Koliatsos VE, Tessarollo L (1999) Brain-
derived neurotrophic factor-deficient mice develop aggressive-
ness and hyperphagia in conjunction with brain serotonergic 
abnormalities. Proc Natl Acad Sci USA 96:15239–15244
 46. Mellios N, Huang HS, Grigorenko A, Rogaev E, Akbarian S 
(2008) A set of differentially expressed miRNAs, including miR-
30a-5p, act as post-transcriptional inhibitors of BDNF in prefron-
tal cortex. Hum Mol Genet 17:3030–3042
 47. Miura P, Amirouche A, Clow C, Belanger G, Jasmin BJ (2012) 
Brain-derived neurotrophic factor expression is repressed during 
myogenic differentiation by miR-206. J Neurochem 120:230–238
 48. Moore MJ (2005) From birth to death: the complex lives of 
eukaryotic mRNAs. Science 309:1514–1518
 49. Mousavi K, Jasmin BJ (2006) BDNF is expressed in skeletal 
muscle satellite cells and inhibits myogenic differentiation. J 
Neurosci 26:5739–5749
 50. Nakajo Y, Miyamoto S, Nakano Y, Xue JH, Hori T, Yanamoto H 
(2008) Genetic increase in brain-derived neurotrophic factor lev-
els enhances learning and memory. Brain Res 1241:103–109
 51. Park H, Poo MM (2013) Neurotrophin regulation of neural circuit 
development and function. Nat Rev Neurosci 14:7–23
 52. Peltier HJ, Latham GJ (2008) Normalization of microRNA 
expression levels in quantitative RT-PCR assays: identification of 
suitable reference RNA targets in normal and cancerous human 
solid tissues. RNA 14:844–852
 53. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pan-
dolfi PP (2010) A coding-independent function of gene and pseu-
dogene mRNAs regulates tumour biology. Nature 465:1033–1038
 54. Radzikinas K, Aven L, Jiang Z, Tran T, Paez-Cortez J, Boppidi K, 
Lu J, Fine A, Ai X (2011) A Shh/miR-206/BDNF cascade coordi-
nates innervation and formation of airway smooth muscle. J Neu-
rosci 31:15407–15415
 55. Rios M, Fan G, Fekete C, Kelly J, Bates B, Kuehn R, Lechan 
RM, Jaenisch R (2001) Conditional deletion of brain-derived 
neurotrophic factor in the postnatal brain leads to obesity and 
hyperactivity. Mol Endocrinol 15:1748–1757
 56. Saetrom P, Heale BS, Snove O Jr, Aagaard L, Alluin J, Rossi JJ 
(2007) Distance constraints between microRNA target sites dic-
tate efficacy and cooperativity. Nucleic Acids Res 35:2333–2342
 57. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP (2011) A 
ceRNA hypothesis: the Rosetta Stone of a hidden RNA lan-
guage? Cell 146:353–358
 58. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB (2008) 
Proliferating cells express mRNAs with shortened 3′ untrans-
lated regions and fewer microRNA target sites. Science 
320:1643–1647
 59. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky 
E, Ambros V (2004) Expression profiling of mammalian micro-
RNAs uncovers a subset of brain-expressed microRNAs with 
possible roles in murine and human neuronal differentiation. 
Genome Biol 5:R13
 60. Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosen-
bloom K, Clawson H, Spieth J, Hillier LW, Richards S, Wein-
stock GM, Wilson RK, Gibbs RA, Kent WJ, Miller W, Haussler 
D (2005) Evolutionarily conserved elements in vertebrate, insect, 
worm, and yeast genomes. Genome Res 15:1034–1050
 61. Timmusk T, Palm K, Metsis M, Reintam T, Paalme V, Saarma 
M, Persson H (1993) Multiple promoters direct tissue-specific 
expression of the rat BDNF gene. Neuron 10:475–489
 62. Timmusk T, Persson H, Metsis M (1994) Analysis of transcrip-
tional initiation and translatability of brain-derived neurotrophic 
factor mRNAs in the rat brain. Neurosci Lett 177:27–31
 63. Trang T, Beggs S, Salter MW (2011) Brain-derived neurotrophic 
factor from microglia: a molecular substrate for neuropathic pain. 
Neuron Glia Biology 7:99–108
 64. Tyler WJ, Alonso M, Bramham CR, Pozzo-Miller LD (2002) 
From acquisition to consolidation: on the role of brain-derived 
neurotrophic factor signaling in hippocampal-dependent learning. 
Learn Mem 9:224–237
 65. Yaffe D, Saxel O (1977) Serial passaging and differentiation of 
myogenic cells isolated from dystrophic mouse muscle. Nature 
270:725–727
 66. Yajima Y, Narita M, Usui A, Kaneko C, Miyatake M, Yamaguchi 
T, Tamaki H, Wachi H, Seyama Y, Suzuki T (2005) Direct evi-
dence for the involvement of brain-derived neurotrophic factor in 
the development of a neuropathic pain-like state in mice. J Neu-
rochem 93:584–594
 67. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth 
AN, Tsuchihashi T, McManus MT, Schwartz RJ, Srivastava D 
(2007) Dysregulation of cardiogenesis, cardiac conduction, and 
cell cycle in mice lacking miRNA-1-2. Cell 129:303–317
 68. Zhao Y, Samal E, Srivastava D (2005) Serum response factor 
regulates a muscle-specific microRNA that targets Hand2 during 
cardiogenesis. Nature 436:214–220
 69. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, 
Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, 
Timmusk T, Sipione S, Cattaneo E (2001) Loss of huntingtin-
mediated BDNF gene transcription in Huntington’s disease. Sci-
ence 293:493–498
